A Randomized Controlled Study Of Transcatheter Arterial Chemoembolization Combined With Autologous DC-CIK Cells In The Treatment Of Advanced Hepatocellular Carcinoma

BackgroundTranscatheter arterial chemoembolization is a minimally invasive techniques in thetreatment of hepatocellular carcinoma. A series of studies showed that TACE is a goodchoice for hepatocellular carcinoma patients with good liver function in early, middle andadvanced stages,and it can prolong overall survival. For patients with advancedhepatocellular carcinoma with vascular invasion, now the view that " Portal veinthrombosis is not an absolute contraindication, Only portal vein tumor thrombus causingsignificant portal hypertension, Such as massive ascites, esophageal varices, is not suitbaleto TACE. However, after the obvious formation of collateral circulation in portal,you canstill perform Transcatheter arterial chemoembolization.” Therefore, patients with advancedhepatocellular carcinoma associated with other underlying diseases suah as cirrhosis,portal thrombosis, multiple intrahepatic and distant metastasis,who are unsuitable for othertreatment,always prefer TACE to control intrahepatic lesions and delay tumorprogression.TACE can induce tumor necrosis and have little damage to de body,so it hascertain advantages in the treatment of hepatocellular carcinoma. But TACE can not makecomplete necrosis of tumor lesions, and it also can damage the patient’s immune function,the residual activity after treatment of lesions and decreased immune function oftenaggravate liver cancer local recurrence and distant metastasis.After a long period of exploration, people recognized that immunotherapy play animportant role in tumor therapy.More popular in recent years, DC-CIK cell can kill tumorcells, regulating immune function and have certain effect in preventing tumor fromrecurrence and metastasis. In this study, we combine Transcatheter arterialchemoembolization with DC-CIK cell therapy in the treatment of advanced primary livercancer patients,and compare the effects with Transcatheter arterial chemoembolizationonly.ObjectiveTo compare the treatment effect of hepatic arterial chemoembolization (TACE)combined with DC-CIK biotherapy treatment with TACE alone on the patients withPrimary hepatocellular carcinoma in BCLC C stages．MethodsPatients were divided into treatment group and control group.The treatment group underwent combined treatment and the control group only received TACE treatment.Evaluation of immune function, survival, clinical efficacy after treatment.Results1. The number of Peripheral blood lymphocytes of patients Significantly reducedafter TACE treatment(P＜0.01)；free．The percentages of Lymphocyte subsets is nosignificant difference before and after TACE treatment(P>0．05).2. CD3+CD8+T lymphocytes increase and CD3+CD4+T lymphocytes decreasesignificantly after CIK cells transfusion(P<0.05). CD3+、CD3-CD56+NK、CD3+CD8+lymphocytes increase insignificantly after CIK cells transfusion(P>0.05).3. Control group:20cases were followed up, nine cases survived six months;treatment groups: follow-up of24cases,19cases survived six months. There arestatistically significant differences between the treatment group and the control groupsurvival.4. The mental state and physical condition, such as self-comfort of treatment groupare better than that of the control group.ConclusionThe immune function and the quality of life improve after sequential therapy of TACEand DC-CIK cell treatment．And six-month survival rate has improved significantly.